Product apis-angiogenesis

Home > products > apis> angiogenesis

Catalog	name	Description	price
R-C-656	Voxtalisib (XL765) CAS:934493-76-2	Voxtalisib(XL765)is a potent PI3K inhibitor,which has a similar activity toward class I PI3K (IC50s=39,113,9 and 43 nM for p110α,p110β,p110γ and p110δ, respectively),also inhibits DNA-PK(IC50=150 nM) and mTOR(IC50=157 nM).Voxtalisib (XL765)inhibits mTORC1 and mTORC2 with IC50s of 160 and 910 nM, respectively.	price>
R-C-657	ENMD2076 cas:934353-76-1	ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM,25-fold selective for Aurora A than over Aurora B and less potent to RET,SRC,NTRK1/TRKA,CSF1R/FMS,VEGFR2/KDR,FGFR and PDGFRα.ENMD-2076 inhibits the growth of a wide range of human solid tumor and hematopoietic cancer cell lines with IC50 from 0.025 to 0.7 μM,which induces apoptosis and G2/M phase arrest.	price>
R-C-676	AVL-292 cas:1202757-89-8	Spebrutinib(CC-292,AVL-292) is a covalent,orally active, and highly selective BTK inhibitor with IC50 of <0.5 nM,displaying at least 1400-fold selectivity over the other kinases assayed.	price>
R-R-2425	Revumenib CAS No.2169919-21-3	Revumenib (SNDX-5613)/CAS No.2169919-21-3 is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).	price>
R-C-735	Plinabulin (NPI-2358) CAS NO. 714272-27-2	NPI-2358 is a synthetic analog of NPI-2350,a natural product isolated from Aspergillus sp.,which depolymerizes microtubules in A549 human lung carcinoma cells.	price>
R-C-754	GNF-5 cas:778277-15-9	GNF-5,an analogue of GNF-2 with improved pharmacokinetic properties,is a selective non-ATP competitive inhibitor of Bcr-Abl with an IC50 value of 0.22±0.1 uM (Wild type Abl).	price>
R-C-976	Quizartinib (AC220) cas:950769-58-1	Quizartinib(AC220)is an orally active, highly selective and potent second-generation type II FLT3 tyrosine kinase inhibitor,with a Kd of 1.6 nM. Quizartinib inhibits wild-type FLT3 and FLT3-ITD autophosphorylation in MV4-11 cells with IC50s of 4.2 and 1.1 nM,respectively.Quizartinib can be linked to the VHL ligand via an optimized linker to form a PROTAC FLT3 degrader.Quizartinib induces apoptosis.	price>
R-C-984	Bosutinib(SKI-606) CAS:380843-75-4	Bosutinib(SKI-606)is a novel,dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays,respectively.Bosutinib also effectively decreases the activity of PI3K/AKT/mTOR,MAPK/ERK and JAK/STAT3 signaling pathways by blocking the phosphorylation levels of p-ERK,p-S6,and p-STAT3.Bosutinib promotes autophagy.	price>
R-C-1048	VS-4718(PND1186) CAS No. 1061353-68-1	PND-1186(VS-4718)is a potent, highly-specific and reversible inhibitor of FAK with an IC50 of 1.5 nM.PND-1186 selectively promotes tumor cell apoptosis.PND-1186 is an effective FAK inhibitor with IC50 of 1.5 nm.Pnd-1186 did not change the tyrosine phosphorylation of c-Src or p130cas,but inhibited cell movement.	price>
R-C-1049	WH-4-023 cas: 837422-57-8	WH-4-023(KIN001-112,KIN112,Dual LCK/SRC inhibitor)is a potent and orally active Lck/Src inhibitor with IC50s of 2 nM and 6 nM in cell-free assays, respectively.Exhibits>300-fold selectivity against p38α and KDR.Also potently inhibits SIK(IC50 values are 10,22 and 60 nM for SIK 1,2 and 3 respectively)and displays selectivity over a range of closely related kinases.	price>

...